A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

BACKGROUND: Recent studies have demonstrated that synthetic dsRNAs may produce therapeutic effects in a target-independent manner through stimulation of the toll-like receptor-3 (TLR3)/interferon pathway; as a result, angiogenesis and proliferation of tumor cells are inhibited. Thus, this pathway ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yu-Yin, Chen, Li, Wang, Gui-Lan, Zhou, Jia-Ming, Zhang, Yi-Xin, Wei, Yin-Ze, Zhu, Yuan-Yuan, Qin, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827827/
https://www.ncbi.nlm.nih.gov/pubmed/24195809
http://dx.doi.org/10.1186/1471-2407-13-527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827827/
https://www.ncbi.nlm.nih.gov/pubmed/24195809
http://dx.doi.org/10.1186/1471-2407-13-527

Ejemplares similares